Monopar Therapeutics Inc. Investment Income, Interest
Monopar Therapeutics Inc. (MNPR) reported Investment Income, Interest of $1.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-12
- Monopar Therapeutics Inc. investment income, interest for the quarter ending 2026-06-30 was $1.30M, a 66.40% increase year-over-year.
- Monopar Therapeutics Inc. investment income, interest for the quarter ending 2026-03-31 was $1.33M, a 123.21% increase year-over-year.
- Monopar Therapeutics Inc. investment income, interest for the quarter ending 2025-12-31 was $954.43K, a 540.41% increase year-over-year.
- Monopar Therapeutics Inc. investment income, interest for the quarter ending 2025-09-30 was $655.47K, a 559.80% increase year-over-year.
- Monopar Therapeutics Inc. investment income, interest for fiscal 2025 was $2.99M, a 639.45% increase from fiscal 2024.
- Monopar Therapeutics Inc. investment income, interest for fiscal 2024 was $404.02K, a 5.83% decline from fiscal 2023.
- Monopar Therapeutics Inc. investment income, interest for fiscal 2023 was $429.04K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.30M 10-Q · filed 2026-08-12 | $2.63M 10-Q · filed 2026-08-12 | $3.59M derived: sum of 3 quarters · filed 2026-08-12 | $4.24M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.33M 10-Q · filed 2026-05-14 | $2.29M derived: sum of 2 quarters · filed 2026-05-14 | $2.94M derived: sum of 3 quarters · filed 2026-05-14 | $3.72M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $954.43K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.61M derived: sum of 2 quarters · filed 2026-03-27 | $2.39M derived: sum of 3 quarters · filed 2026-08-12 | $2.99M 10-K · filed 2026-03-27 |
| 2025-09-30 | $655.47K 10-Q · filed 2025-11-13 | $1.44M derived: sum of 2 quarters · filed 2026-08-12 | $2.03M 10-Q · filed 2025-11-13 | $2.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $780.77K 10-Q · filed 2026-08-12 | $1.38M 10-Q · filed 2026-08-12 | $1.53M derived: sum of 3 quarters · filed 2026-08-12 | $1.63M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $596.85K 10-Q · filed 2026-05-14 | $745.88K derived: sum of 2 quarters · filed 2026-05-14 | $845.23K derived: sum of 3 quarters · filed 2026-05-14 | $918.70K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $149.04K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $248.38K derived: sum of 2 quarters · filed 2026-03-27 | $321.86K derived: sum of 3 quarters · filed 2026-03-27 | $404.02K 10-K · filed 2026-03-27 |
| 2024-09-30 | $99.34K 10-Q · filed 2025-11-13 | $172.82K derived: sum of 2 quarters · filed 2025-11-13 | $254.98K 10-Q · filed 2025-11-13 | $353.06K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $73.47K 10-Q · filed 2025-08-12 | $155.64K 10-Q · filed 2025-08-12 | $253.71K derived: sum of 3 quarters · filed 2025-08-12 | $365.97K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $82.17K 10-Q · filed 2025-05-13 | $180.24K derived: sum of 2 quarters · filed 2025-05-13 | $292.50K derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $98.07K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $210.33K derived: sum of 2 quarters · filed 2025-03-31 | $429.04K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $112.26K 10-Q · filed 2024-11-08 | $330.97K 10-Q · filed 2024-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |